Semaglutide benefits for HFpEF ‘largest seen with any agent’, researchers claim
Patients taking the GLP-1 receptor agonist showed greater symptom improvement and weight loss, say doctors.
Semaglutide may be a new therapeutic option for obesity-related heart failure with preserved ejection fraction, with results from a landmark study showing substantial reductions in symptom burden.
The Novo Nordisk–funded trial found that patients given the GLP-1 receptor agonist had a twofold improvement in symptoms and physical limitations, as well as fewer adverse heart failure events, compared with those given placebo.
